Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | STAT1 | P42224 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | STAT3 | P40763 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8267163 | 0.87 | SMN1; SMN2 (0.88) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 | |
| SCHEMBL8267289 | 0.85 | RAB9A (1.00) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL10192041 | 0.83 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 | |
| SCHEMBL8267293 | 0.82 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 | |
| SCHEMBL14074104 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 | |
| SCHEMBL8266868 | 0.81 | RAB9A (0.77) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 | |
| SCHEMBL27179495 | 0.81 | MAPT (0.71) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 | |
| SCHEMBL30926778 | 0.81 | MAPT (0.71) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 | |
| SCHEMBL8267156 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 | |
| SCHEMBL11534377 | 0.81 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9AALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE | 2011-10-20 | — | — | US | claimed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | claimed |
| EP-2181091-A2 | AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2010-05-05 | — | — | EP | claimed |
| WO-2009010454-A2 | AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2009-01-22 | — | — | WO | claimed |
| US-8524726-B2 | Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-30 | — | — | US | disclosed |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE | 2011-10-20 | — | — | US | disclosed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | disclosed |
| EP-2181091-A2 | AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009010454-A2 | AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-7291743-B2 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291743-B2 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | SMN1; SMN2 1604/4885NPC1 2148/4885RAB9A 1653/4885 |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | SMN1; SMN2 1604/4885NPC1 2148/4885RAB9A 1653/4885 |
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | GRM4, GRM1, GRM3 | SMN1; SMN2 1604/4885NPC1 2148/4885RAB9A 1653/4885 |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | SMN1; SMN2 1604/4885NPC1 2148/4885RAB9A 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.